Company / Shareholders' Equity
Biogen Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$18.3B
FY2025
5-year range
$10.9B / $18.3B
FY2021-FY2025
Trend
+9.2%
vs FY2024
Sector context
#9 of 215
Health Care
What the data says
Among 215 Health Care companies, Biogen is in the top 4% for shareholders' equity. Shareholders' Equity has increased for 5 consecutive years, from $10.7B in FY2020 to $18.3B in FY2025.
Based on SEC 10-K filings.
$18.3B in FY2025 with a 5-year CAGR of +11.3%. Top quartile in the Health Care sector.
Improved from $14.8B to $18.3B over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +10.9%
- 5-Year CAGR
- +11.3%
- 10-Year CAGR
- -
Sector benchmark
Top 4% in Health CareTop 4% of 215This company $18.3B Sector average $2.6B
▼
+613.0% above sector average
Key checks
Key Insights
- Biogen's shareholders' equity has grown for 5 consecutive years.
- 5-year CAGR of +11.3%, indicating consistent growth.
- In FY2025, shareholders' equity increased 9.2% year-over-year.
- Ranks #9 out of 215 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $18.3B | +9.2% |
| FY2024 | $16.7B | +13.0% |
| FY2023 | $14.8B | +10.5% |
| FY2022 | $13.4B | +23.0% |
| FY2021 | $10.9B | +1.8% |
| FY2020 | $10.7B | -19.8% |
| FY2019 | $13.3B | +2.3% |
| FY2018 | $13.0B | +3.4% |
| FY2017 | $12.6B | +3.9% |
| FY2016 | $12.1B | +29.5% |
As of FY2025 · SEC 10-K · Updated Mar 3, 2026